CpG methylation analysis - Current status of clinical assays and potential applications in molecular diagnostics: A report of the association for molecular pathology

Journal of Molecular Diagnostics

Volumn 11, Issue 4, 2009, Pages 266-278

  Sepulveda, Antonia R ^a,b   Jones, Dan ^a,c   Ogino, Shuji ^a,d   Samowitz, Wade ^a,e   Gulley, Margaret L ^a,f   Edwards, Robin ^a,g   Levenson, Victor ^a,h   Pratt, Victoria M ^a,i   Yang, Bin ^a,j   Nafa, Khedoudja ^a,k   Yan, Liying ^a,l   Vitazka, Patrick ^a,m  

^a Association for Molecular Pathology   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e ARUP LABORATORIES   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g PFIZER INC   (United States)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

ⁱ QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^j LERNER RESEARCH INSTITUTE   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l EpigenDx   (United States)

^m VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALKYLATING AGENT; AZACITIDINE; BISULFITE; CYCLOPHOSPHAMIDE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; RESTRICTION ENDONUCLEASE; TEMOZOLOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ASSAY; B CELL LYMPHOMA; BACTERIAL INFECTION; BILE DUCT CANCER; BODY FLUID; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; COLORECTAL CANCER; CPG ISLAND; CYTOLOGY; DECISION MAKING; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; ESOPHAGUS CARCINOMA; GLIOBLASTOMA; HUMAN; INFECTION; INFLAMMATORY DISEASE; LYMPHOMA; METHYLATION; MYELODYSPLASTIC SYNDROME; NEOPLASM; PANCREAS CANCER; PREDICTION; PROGNOSIS; QUALITATIVE ANALYSIS; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REVIEW; SCREENING; STANDARDIZATION; TREATMENT RESPONSE; TUMOR GROWTH; URINALYSIS; UROGENITAL TRACT CANCER; UTERINE CERVIX CARCINOMA; VALIDATION STUDY; VIRUS;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CPG ISLANDS; DISEASE PROGRESSION; DNA METHYLATION; DNA RESTRICTION ENZYMES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, DNA; SULFITES; TUMOR MARKERS, BIOLOGICAL;

EID: 69249114294     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2009.080125     Document Type: Article

References (156)

1. Gardiner-Garden M, Frommer M: CpG islands in vertebrate genomes. J Mol Biol 1987, 196:261-282
2. Takai D, Jones PA: Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA 2002, 99:3740-3745
3. Ehrich M, Nelson M, Stanssens P, Zabeau M, Liloglou T, Xinarianos G, Cantor C, Field J, van den Boom D: Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci USA 2005, 102: 15785-15790
4. Avramis V, Mecum R, Nyce J, Steele D, Holcenberg J: Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabino-furanosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia. Cancer Chemother Pharmacol 1989, 24:203-210
5. Hoque MO, Feng Q, Toure P, Dem A, Critchlow CW, Hawes SE, Wood T, Jeronimo C, Rosenbaum E, Stern J, Yu M, Trink B, Kiviat NB, Sidransky D: Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 2006, 24:4262-4269
6. Leung WK, To KF, Man EP, Chan MW, Bai AH, Hui AJ, Chan FK, Sung JJ: Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am J Gastroenterol 2005, 100:2274-2279
7. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992, 89:1827-1831
8. Mikeska T, Bock C, El-Maarri O, Hubner A, Ehrentraut D, Schramm J, Felsberg J, Kahl P, Buttner R, Pietsch T, Waha A: Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn 2007, 9:368-381
9. Schatz P, Dietrich D, Schuster M: Rapid analysis of CpG methylation patterns using RNase T1 cleavage and MALDI-TOF. Nucleic Acids Res 2004, 32:e167
10. Matin MM, Baumer A, Hornby DP: An analytical method for the detection of methylation differences at specific chromosomal loci using primer extension and ion pair reverse phase HPLC. Hum Mutat 2002, 20:305-311
11. Huang TH, Perry MR, Laux DE: Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet 1999, 8:459-470
12. Yan PS, Perry MR, Laux DE, Asare AL, Caldwell CW, Huang TH: CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer. Clin Cancer Res 2000, 6:1432-1438
13. Yan P, Efferth T, Chen H, Lin J, Rodel F, Fuzesi L, Huang T: Use of CpG island microarrays to identify colorectal tumors with a high degree of concurrent methylation. Methods 2002, 27:162-169
14. Bibikova M, Lin Z, Zhou L, Chudin E, Garcia E, Wu B, Doucet D, Thomas N, Wang Y, Vollmer E, Goldmann T, Seifart C, Jiang W, Barker D, Chee M, Floros J, Fan J: High-throughput DNA methylation profiling using universal bead arrays. Genome Res 2006, 16:383-393
15. Cheng YW, Shawber C, Notterman D, Paty P, Barany F: Multiplexed profiling of candidate genes for CpG island methylation status using a flexible PCR/LDR/Universal Array assay. Genome Res 2006, 16:282-289
16. Fukasawa M, Kimura M, Moritas S, Matsubara K, Yamanaka S, Endo C, Sakurada A, Sato M, Kondo T, Horii A, Sasaki H, Hatada I: Microarray analysis of promoter methylation in lung cancers. J Hum Genet 2006, 51:368-374
17. Schumacher A, Kapranov P, Kaminsky Z, Flanagan J, Assadzadeh A, Yau P, Virtanen C, Winegarden N, Cheng J, Gingeras T, Petronis A: Microarray-based DNA methylation profiling: technology and applications. Nucleic Acids Res 2006, 34:528-542
18. Grunau C, Clark SJ, Rosenthal A: Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acid Research 2001, 29:E65
19. Warnecke PM, Stirzaker C, Melki JR, Millar DS, Paul CL, Clark SJ: Detection and measurement of PCR bias in quantitative methylation analysis of bisulphite-treated DNA. Nucleic Acids Res 1997, 25:4422-4426
20. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:9821-9826
21. Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, Makrigiorgos GM, Weisenberger DJ, Laird PW, Loda M, Fuchs CS: Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006, 8:209-217
22. Wang Y, Zheng W, Luo J, Zhang D, Zuhong L: In situ bisulfite modification of membrane-immobilized DNA for multiple methylation analysis. Anal Biochem 2006, 359:183-188
23. Kerjean A, Vieillefond A, Thiounn N, Sibony M, Jeanpierre M, Jouannet P: Bisulfite genomic sequencing of microdissected cells. Nucleic Acids Res 2001, 29:E106-E106
24. Laird PW: The power and the promise of DNA methylation markers. Nat Rev Cancer 2003, 3:253-266
25. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW: MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000, 28:E32
26. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Danenberg PV, Laird PW: CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res 1999, 59:2302-2306
27. Akey DT, Akey JM, Zhang K, Jin L: Assaying DNA methylation based on high-throughput melting curve approaches. Genomics 2002, 80:376-384
28. Thomassin H, Kress C, Grange T: MethylQuant: a sensitive method for quantifying methylation of specific cytosines within the genome. Nucleic Acids Res 2004, 32:e168
29. Zeschnigk M, Bohringer S, Price EA, Onadim Z, Masshofer L, Lohmann DR: A novel real-time PCR assay for quantitative analysis of methylated alleles (QAMA): analysis of the retinoblastoma locus. Nucleic Acids Res 2004, 32:e125
30. Cottrell SE, Distler J, Goodman NS, Mooney SH, Kluth A, Olek A, Schwope I, Tetzner R, Ziebarth H, Berlin K: A real-time PCR assay for DNA-methylation using methylation-specific blockers. Nucleic Acids Res 2004, 32:e10
31. Xiong Z, Laird PW: COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997, 25:2532-2534
32. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R: Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites. Biotechniques 2003, 35:146-150
33. Uhlmann K, Brinckmann A, Toliat MR, Ritter H, Nurnberg P: Evaluation of a potential epigenetic biomarker by quantitative methylsingle nucleotide polymorphism analysis. Electrophoresis 2002, 23:4072-4079
34. Tost J, Dunker J, Gut IG: Analysis and quantification of multiple methylation variable positions in CpG islands by pyrosequencing. Biotechniques 2003, 35:152-156
35. EL-Maarri O, Herbibiaux U, Walter J, Oldenburg J: A rapid, quantitative, non-radioactive bisulfite-SNuPE-IP RP HPLC assay for methylation analysis at specific CpG sites. Nucleic Acids Research 2002, 30:E25
36. Deng D, Deng G, Smith MF, Zhou J, Xin H, Powell SM, Lu Y: Simultaneous detection of CpG methylation and single nucleotide polymorphism by denaturing high performance liquid chromatography. Nucleic Acids Res 2002, 30:E13
37. Waalwijk C, Flavell RA: DNA methylation at a CCGG sequence in the large intron of the rabbit beta-globin gene: tissue-specific variations. Nucleic Acids Res 1978, 5:4631-4634
38. Shen CK, Maniatis T: Tissue-specific DNA methylation in a cluster of rabbit beta-like globin genes. Proc Natl Acad Sci USA 1980, 77:6634-6638
39. Singer-Sam J, Grant M, LeBon JM, Okuyama K, Chapman V, Monk M, Riggs AD: Use of a HpaII-polymerase chain reaction assay to study DNA methylation in the Pgk-1 CpG island of mouse embryos at the time of X-chromosome inactivation. Mol Cell Biol 1990, 10:4987-4989
40. Melnikov AA, Scholtens DM, Wiley EL, Khan SA, Levenson VV. Array-based multiplex analysis of DNA methylation in breast cancer tissues. J Mol Diagn 2008, 10:93-101.
41. Hayashizaki Y, Hirotsune S, Okazaki Y, Hatada I, Shibata H, Kawai J, Hirose K, Watanabe S, Fushiki S, Wada S, Sugimoto T, Kobayakawa K, Kawara T, Katsuki M, Shibuya T, Mukai T: Restriction landmark genomic scanning method and its various applications. Electrophoresis 1993, 14:251-258
42. Plass C, Shibata H, Kalcheva I, Mullins L, Kotelevtseva N, Mullins J, Kato R, Sasaki H, Hirotsune S, Okazaki Y, Held WA, Hayashizaki Y, Chapman VM: Identification of Grf1 on mouse chromosome 9 as an imprinted gene by RLGS-M. Nat Genet 1996, 14:106-109
43. Toyota M, Ho C, Ahuja N, Jair KW, Li Q, Ohe-Toyota M, Baylin SB, Issa JP: Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 1999, 59:2307-2312
44. Gonzalgo ML, Liang G, Spruck CH, 3rd, Zingg JM, Rideout WM, 3rd, Jones PA: Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR. Cancer Res 1997, 57:594-599
45. Estecio MR, Yan PS, Ibrahim AE, Tellez CS, Shen L, Huang TH, Issa JP: High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res 2007, 17:1529-1536
46. Wei SH, Balch C, Paik HH, Kim YS, Baldwin RL, Liyanarachchi S, Li L, Wang Z, Wan JC, Davuluri RV, Karlan BY, Gifford G, Brown R, Kim S, Huang TH, Nephew KP: Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res 2006, 12:2788-2794
47. Chen CM, Chen HL, Hsiau TH, Hsiau AH, Shi H, Brock GJ, Wei SH, Caldwell CW, Yan PS, Huang TH: Methylation target array for rapid analysis of CpG island hypermethylation in multiple tissue genomes. Am J Pathol 2003, 163:37-45
48. Melnikov AA, Gartenhaus RB, Levenson AS, Motchoulskaia NA, Levenson Chernokhvostov VV: MSRE-PCR for analysis of gene-specific DNA methylation. Nucleic Acids Res 2005, 33:e93
49. Kagan J, Srivastava S, Barker P, A. S., Belinsky S, Cairns P: Towards clinical application of methylated DNA sequences as cancer biomarkers: a Joint NCI's EDRN and NIST workshop on standards, methods, assays, reagents, and tools. Cancer Res 2007, 67:4545-4549
50. Li L, Dahiya R: MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002, 18:1427-1431
51. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B, Levine J, Kim M, French AJ, Thibodeau SN, Jass J, Haile R, Laird PW: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006, 38:787-793
52. Toyooka KO, Toyooka S, Maitra A, Feng Q, Kiviat NC, Smith A, Minna JD, Ashfaq R, Gazdar AF: Establishment and validation of real-time polymerase chain reaction method for CDH1 promoter methylation. Am J Pathol 2002, 161:629-634
53. Brena RM, Morrison C, Liyanarachchi S, Jarjoura D, Davuluri RV, Otterson GA, Reisman D, Glaros S, Rush LJ, Plass C: Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer. PLoS Med 2007, 4:e108
54. Kominato Y, Hata Y, Takizawa H, Tsuchiya T, Tsukada J, Yamamoto F: Expression of human histo-blood group ABO genes is dependent upon DNA methylation of the promoter region. J Biol Chem 1999, 274:37240-37250
55. Kelavkar UP, Harya NS, Hutzley J, Bacich DJ, Monzon FA, Chandran U, Dhir R, O'Keefe DS: DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation. Prostaglandins Other Lipid Mediat 2007, 82:185-197
56. Ogino S, kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS: Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 2007, 9:305-314
57. Coleman WB, Rivenbark AG: Quantitative DNA methylation analysis: the promise of high-throughput epigenomic diagnostic testing in human neoplastic disease. J Mol Diagn 2006, 8:152-156
58. Samowitz W: The CpG island methylator phenotype in colorectal cancer. J Mol Diagn 2007, 9:281-283
59. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP: CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999, 96:8681-8686
60. Hawkins N, Norrie M, Cheong K, Mokany E, Ku SL, Meagher A, O'Connor T, Ward R: CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 2002, 122:1376-1387
61. Whitehall VL, Wynter CV, Walsh MD, Simms LA, Purdie D, Pandeya N, Young J, Meltzer SJ, Leggett BA, Jass JR: Morphological and molecular heterogeneity within nonmicrosatellite instability-high colorectal cancer. Cancer Res 2002, 62:6011-6014
62. Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, Wolff RK, Slattery ML: Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005, 129:837-845
63. Grady WM: CIMP and colon cancer gets more complicated. Gut 2007, 56:1498-1500
64. Teodoridis JM, Hardie C, Brown R. CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett 2008, 268:177-186
65. Deng G, Bell I, Crawley S, Gum J, Terdiman JP, Allen BA, Truta B, Sleisenger MH, Kim YS: BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004, 10:191-195
66. Hitchins MP, Wong JJ, Suthers G, Suter CM, Martin DI, Hawkins NJ, Ward RL: Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med 2007, 356:697-705
67. Ogino S, Cantor M, Kawasaki T, Brahmandam M, Kirkner G, Weisenberger DJ, Campan M, Laird PW, Loda M, Fuchs CS: CpG island methylator phenotype (CIMP) of colorectal cancer is best characterized by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006, 55:1000-1006
68. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, Compton C, Mayer RJ, Goldberg R, Bertagnolli MM, Boland CR: The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 2007, 132:127-138
69. Samowitz WS, Slattery ML, Sweeney C, Herrick J, Wolff RK, Albertsen H: APC mutations and other genetic and epigenetic changes in colon cancer. Mol Cancer Res 2007, 5:165-170
70. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Meyerhardt JA, Fuchs CS, Ogino S: Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Neoplasia 2007, 9:569-577
71. Ogino S, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs CS: LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG methylator phenotype in colorectal cancer. Int J Cancer 2008, 122:2767-2773
72. Toyota M, Issa JP: The role of DNA hypermethylation in human neoplasia. Electrophoresis 2000, 21:329-333
73. Kambara T, Simms LA, Whitehall VL, Spring KJ, Wynter CV, Walsh MD, Barker MA, Arnold S, McGivern A, Matsubara N, Tanaka N, Higuchi T, Young J, Jass JR, Leggett BA: BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004, 53:1137-1144
74. McGivern A, Wynter CV, Whitehall VL, Kambara T, Spring KJ, Walsh MD, Barker MA, Arnold S, Simms LA, Leggett BA, Young J, Jass JR: Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer 2004, 3:101-107
75. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS: CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 2006, 8:582-588
76. Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, Hernandez NS, Chen X, Ahmed S, Konishi K, Hamilton SR, Issa JP: Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 2007, 104:18654-18659
77. Ogino S, Goel A: Molecular classification and correlates in colorectal cancer. J Mol Diagn 2008, 10:13-27
78. Ogino S, Kawasaki T, Kirkner GJ, Ohnishi M, Fuchs CS: 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. BMC Cancer 2007, 7:72
79. Ogino S, Kawasaki T, Kirkner GJ, Suemoto Y, Meyerhardt JA, Fuchs CS. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut 2007, 56:1564-1571
80. Kawasaki T, Ohnishi M, Nosho K, Suemoto Y, Kirkner GJ, Meyerhardt JA, Fuchs CS, Ogino S: CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only fewer methylated CIMP-high-specific CpG island, but also low-level methylation in individual loci. Mod Pathol 2008, 21:245-255
81. Oliveira C, Westra JL, Arango D, Ollikainen M, Domingo E, Ferreira A, Velho S, Niessen R, Lagerstedt K, Alhopuro P, Laiho P, Veiga I, Teixeira MR, Ligtenberg M, Kleibeuker JH, Sijmons RH, Plukker JT, Imai K, Lage P, Hamelin R, Albuquerque C, Schwartz S, Jr., Lindblom A, Peltomaki P, Yamamoto H, Aaltonen LA, Seruca R, Hofstra RM: Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet 2004, 13:2303-2311
82. Samowitz W, Sweeney C, Herrick J, Albertsen H, Levin T, Murtaugh M, Wolff R, Slattery M: Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005, 65:6063-6069
83. Ward RL, Cheong K, Ku SL, Meagher A, O'Connor T, Hawkins NJ: Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol 2003, 21:3729-3736
84. Schulmann K, Sterian A, Berki A, Yin J, Sato F, Xu Y, Olaru A, Wang S, Mori Y, Deacu E, Hamilton J, Kan T, Krasna MJ, Beer DG, Pepe MS, Abraham JM, Feng Z, Schmiegel W, Greenwald BD, Meltzer SJ: Inactivation of p16. RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk Oncogene 2005, 24:4138-4148
85. Yang B, Guo M, Herman J, Clark D: Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 2003, 163:1101-1107
86. Yang B, House M, Guo M, Herman J, Clark D: Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol 2005, 18:412-420
87. Watanabe H, Okada G, Ohtsubo K, Yao F, Jiang P, Mouri H, Wakabayashi T, Sawabu N: Aberrant methylation of secreted apoptosis-related protein 2 (SARP2) in pure pancreatic juice in diagnosis of pancreatic neoplasms. Pancreas 2006, 32:382-389
88. Falette NS, Fuqua SA, Chamness GC, Cheah MS, Greene GL, McGuire WL: Estrogen receptor gene methylation in human breast tumors. Cancer Res 1990, 50:3974-3978
89. Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE: Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 1994, 54:2552-2555
90. Lapidus RG, Ferguson AT, Ottaviano YL, Parl FF, Smith HS, Weitzman SA, Baylin SB, Issa JP, Davidson NE: Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res 1996, 2:805-810
91. Huynh H, Alpert L, Pollak M: Silencing of the mammary-derived growth inhibitor (MDGI) gene in breast neoplasms is associated with epigenetic changes. Cancer Res 1996, 56:4865-4870
92. Hakkarainen M, Wahlfors J, Myohanen S, Hiltunen MO, Eskelinen M, Johansson R, Janne J: Hypermethylation of calcitonin gene regulatory sequences in human breast cancer as revealed by genomic sequencing. Int J Cancer 1996, 69:471-474
93. Zrihan-Licht S, Weiss M, Keydar I, Wreschner DH: DNA methylation status of the MUC1 gene coding for a breast-cancer-associated protein. Int J Cancer 1995, 62:245-251
94. Kass DH, Shen M, Appel NB, Anderson DE, Saunders GF: Examination of DNA methylation of chromosomal hot spots associated with breast cancer. Anticancer Res 1993, 13:1245-1251
95. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995, 55:4525-4530
96. Yan PS, Rodriguez FJ, Laux DE, Perry MR, Standiford SB, Huang TH: Hypermethylation of ribosomal DNA in human breast carcinoma. Br J Cancer 2000, 82:514-517
97. Jeronimo C, Costa I, Martins MC, Monteiro P, Lisboa S, Palmeira C, Henrique R, Teixeira MR, Lopes C: Detection of gene promoter hypermethylation in fine needle washings from breast lesions. Clin Cancer Res 2003, 9:3413-3417
98. Krassenstein R, Sauter E, Dulaimi E, Battagli C, Ehya H, Klein-Szanto A, Cairns P: Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res 2004, 10:28-32
99. Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E, Soito AB, Hung DT, Ljung B, Davidson NE, Sukumar S: Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 2001, 357:1335-1336
100. Dua RS, Isacke CM, Gui GP: The intraductal approach to breast cancer biomarker discovery. J Clin Oncol 2006, 24:1209-1216
101. Pu RT, Laitala LE, Alli PM, Fackler MJ, Sukumar S, Clark DP: Methylation profiling of benign and malignant breast lesions and its application to cytopathology. Mod Pathol 2003, 16:1095-1101
102. Fackler M, Malone K, Zhang Z, Schilling E, Garrett-Mayer E, Swift-Scanlan T, Lange J, Nayar R, Davidson N, Khan S, Sukumar S: Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res 2006, 12:3306-3310
103. Shinozaki M, Hoon DS, Giuliano AE, Hansen NM, Wang HJ, Turner R, Taback B: Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res 2005, 11:2156-2162
104. Caldeira JR, Prando EC, Quevedo FC, Neto FA, Rainho CA, Rogatto SR: CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer 2006, 6:48
105. Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y, Noguchi S: Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 2005, 11:1380-1385
106. Gustafson K, Furth E, Heitjan D, Fansler Z, Clark D: DNA methylation profiling of cervical squamous intraepithelial lesions using liquid-based cytology specimens: an approach that utilizes receiver-operating characteristic analysis. Cancer 2004, 102:259-268
107. Feng Q, Balasubramanian A, Hawes S, Toure P, Sow P, Dem A, Dembele B, Critchlow C, Xi L, Lu H, McIntosh M, Young A, Kiviat N: Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst 2005, 97:273-282
108. Wang L, Weber D, Deeds D, Biscotti C, Yang B. DNA methylation frofiling distinguishes low grade papillary urothelial carcinoma from reactive urothelia in urine. Mod Pathol 2006, 19:74A (supplement)
109. Bartsch H: Studies on biomarkers in cancer etiology and prevention: a summary and challenge of 20 years of interdisciplinary research. Mutat Res 2000, 462:255-279
110. Georgiadis P, Samoli E, Kaila S, Katsouyanni K, Kyrtopoulos SA: Ubiquitous presence of O6-methylguanine in human peripheral and cord blood DNA. Cancer Epidemiol Biomarkers Prev 2000, 9:299-305
111. Kyrtopoulos SA: DNA adducts in humans after exposure to methylating agents. Mutat Res 1998, 405:135-143
112. Margison GP, Povey AC, Kaina B, Santibanez Koref MF: Variability and regulation of O6-alkylguanine-DNA alkyltransferase. Carcinogenesis 2003, 24:625-635
113. Danam RP, Howell SR, Brent TP, Harris LC: Epigenetic regulation of O6-methylguanine-DNA methyltransferase gene expression by histone acetylation and methyl-CpG binding proteins. Mol Cancer Ther 2005, 4:61-69
114. Soejima H, Zhao W, Mukai T: Epigenetic silencing of the MGMT gene in cancer. Biochem Cell Biol 2005, 83:429-437
115. von Wronski MA, Brent TP: Effect of 5-azacytidine on expression of the human DNA repair enzyme O6-methylguanine-DNA methyltransferase. Carcinogenesis 1994, 15:577-582
116. Wang Y, Kato T, Ayaki H, Ishizaki K, Tano K, Mitra S, Ikenaga M: Correlation between DNA methylation and expression of O6-methylguanine-DNA methyltransferase gene in cultured human tumor cells. Mutat Res 1992, 273:221-330
117. 6-methylguanine DNA methyltransferase in colorectal cancer. J Mol Diagn 2006, 8:68-75
118. 6-methylguanine-DNA methyltransferase in human lung adenocarcinoma relates to high-grade histology and worse prognosis among smokers. Jpn J Cancer Res 2002, 93:184-189
119. 6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 2003, 13:176-184
120. 6- methylguanine-DNA methyltransferase in hepatocellular, gastric, and breast cancers. Ann Surg Oncol 2001, 8:807-816
121. Kaina B, Ochs K, Grosch S, Fritz G, Lips J, Tomicic M, Dunkern T, Christmann M: BER, MGMT, and MMR in defense against alkylationinduced genotoxicity and apoptosis. Prog Nucleic Acid Res Mol Biol 2001, 68:41-54
122. Esteller M, Risques RA, Toyota M, Capella G, Moreno V, Peinado MA, Baylin SB, Herman JG: Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res 2001, 61:4689-4692
123. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R: Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004, 10:1871-1874
124. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003
125. Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L, Garcia-Lopez JL, Piquer J, Safont MJ, Balana C, Sanchez-Cespedes M, Garcia-Villanueva M, Arribas L, Esteller M: CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004, 10:4933-4938
126. Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, Botto B, Rossi D, Gloghini A, Vitolo U, Carbone A, Baylin SB, Herman JG: Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst 2002, 94:26-32
127. 6-methylguanine- DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma. Int J Hematol 2006, 83:341-347
128. Invernizzi P, Biondi ML, Battezzati PM, Perego F, Selmi C, Cecchini F, Podda M, Simoni G: Presence of fetal DNA in maternal plasma decades after pregnancy. Hum Genet 2002, 110:587-591
129. Silva JM, Garcia JM, Dominguez G, Silva J, Miralles C, Cantos B, Coca S, Provencio M, Espana P, Bonilla F: Persistence of tumor DNA in plasma of breast cancer patients after mastectomy. Ann Surg Oncol 2002, 9:71-76
130. Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG: Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005, 11:4037-4043
131. Muller H, Fiegl H, Widschwendter A, Widschwendter M: Prognostic DNA methylation marker in serum of cancer patients. Ann NY Acad Sci 2004, 1022:44-49
132. Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, Marth C, Widschwendter M: DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 2003, 63:7641-5
133. Koyanagi K, Mori T, O'Day S, Martinez S, Wang H, Hoon D: Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res 2006, 66:6111-6117
134. Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD: Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res 2001, 61:900-902
135. Belshaw NJ, Elliott GO, Williams EA, Bradburn DM, Mills SJ, Mathers JC, Johnson IT: Use of DNA from human stools to detect aberrant CpG island methylation of genes implicated in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2004, 13:1495-1501
136. Lenhard K, Bommer GT, Asutay S, Schauer R, Brabletz T, Goke B, Lamerz R, Kolligs FT: Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol 2005, 3:142-149
137. Garcia-Manero G, Kantarjian H, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda W, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa J: Phase I/II study of the combination of 5-aza-2′ -deoxycytidine with valproic acid in patients with leukemia. Blood 2006, 108:3271-3279
138. Mund C, Hackanson B, Stresemann C, Lubbert M, Lyko F: Characterization of DNA demethylation effects induced by 5-Aza-2′-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res 2005, 65:7086-7090
139. Ruter B, Wijermans PW, Lubbert M: DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia. Int J Hematol 2004, 80:128-135
140. Tao Q, Young L, Woodman C, Murray P: Epstein-Barr virus (EBV) and its associated human cancers-genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci 2006, 11:2672-2713
141. Israel B, Kenney S: Virally targeted therapies for EBV-associated malignancies. Oncogene 2003, 22:5122-5130
142. Verma M: Viral genes and methylation. Ann NY Acad Sci 2003, 983:170-180
143. Varier R, Kundu T: Chromatin modifications (acetylation/ deacetylation/ methylation) as new targets for HIV therapy. Curr Pharm Des 2006, 12:1975-1993
144. Tao Q, Robertson K: Stealth technology: how Epstein-Barr virus utilizes DNA methylation to cloak itself from immune detection. Clin Immunol 2003, 109:53-63
145. Minarovits J: Epigenotypes of latent herpesvirus genomes. Curr Top Microbiol Immunol 2006, 310:61-80
146. Li H, Leu Y, Chang Y: Epigenetic changes in virus-associated human cancers. Cell Res 2005, 15:262-271
147. Zheng Z, Baker C: Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci 2006, 11:2286-2302
148. Goel A, Li MS, Nagasaka T, Shin SK, Fuerst F, Ricciardiello L, Wasserman L, Boland CR: Association of JC virus T-antigen expression with the methylator phenotype in sporadic colorectal cancers. Gastroenterology 2006, 130:1950-1961
149. Etoh T, Kanai Y, Ushijima S, al. e. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol 2004, 164:689-699
150. Bhende P, Seaman W, Delecluse H, Kenney S: The EBV lytic switch protein. Z, preferentially binds to and activates the methylated viral genome Nat Genet 2004, 36:1099-1104
151. Gologan A, Graham DY, Sepulveda AR: Molecular markers in helicobacter pylori-associated gastric carcinogenesis. Clin Lab Med 2005, 25:197-222
152. Issa JP: Age-related epigenetic changes and the immune system. Clin Immunol 2003, 109:103-108
153. Hsieh CJ, Klump B, Holzmann K, Borchard F, Gregor M, Porschen R: Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res 1998, 58:3942-3945
154. Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, Arii K, Kaneda A, Tsukamoto T, Tatematsu M, Tamura G, Saito D, Sugimura T, Ichinose M, Ushijima T: High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 2006, 12:989-995
155. Chan AO, Lam SK, Wong BC, Wong WM, Yuen MF, Yeung YH, Hui WM, Rashid A, Kwong YL: Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. Gut 2003, 52:502-506
156. Yao Y, Tao H, Park DI, Sepulveda JL, Sepulveda AR: Demonstration and characterization of mutations induced by helicobacter pylori organisms in gastric epithelial cells. Helicobacter 2006, 11:272-286